← Leaderboards
Edward T. Ryan
Massachusetts General Hospital
$44,052,519
Attributed
$57,793,391
Total exposure
19
Grants
16
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.1M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$35,493,113 · 15
CDC$22,300,278 · 4
By mechanism
U01$29,229,437 · 5
R01$13,350,910 · 4
D43$4,712,916 · 1
R37$4,367,594 · 1
U19$2,254,034 · 1
R21$1,923,763 · 4
Top collaborators
- Regina C Larocque19 shared
- Firdausi Qadri15 shared
- Stephen B. Calderwood5 shared
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Richelle C Charles$6,402,547
- Marcia B Goldberg$29,817,146
- Nathaniel M Alpert$2,012,803
- Tayyaba Hasan$21,611,486
- Paula I Watnick$19,648,431
Others in their field
Top investigators on “Bangladesh”
- Sayera Banu · International Ctr/Diarrhoeal Dis Res$34,849,549
- Habibul Ahsan · Columbia University Health Sciences$27,961,914
- Thomas William Geisbert · Boston University Medical Campus$25,226,137
- Joseph H Graziano · Columbia University Health Sciences$18,807,160
- William A Petri · University Of Virginia$16,375,617
- Christopher Broder · Henry M. Jackson Fdn For The Adv Mil/Med$16,200,377
Research focus
BangladeshMassachusettsVaccine DevelopmentVaccinesPathogenInternational CenterCholeraResearch PersonnelVibrio CholeraeGeneral HospitalsInfectionImmune ResponseUniversitiesResponseProgramsAntigensInternationalImmunityCholera VaccineHouseholdPublic HealthAntibodiesVaccinationSampling
Grant awards (95)
Shigella Conjugate Vaccine (SCV4) Development, Characterization, and Pre-clinical Evaluation$1,143,199
R01 · FY2025 · AI · contact PI
O-Specific Polysaccharide Responses and Cholera$799,285
R37 · FY2025 · AI · contact PI
Functional profiling of OSP-specific and other antibodies during shigella infection$633,143
R01 · FY2025 · AI · contact PI
International research training program in vaccine development and public health$285,001
D43 · FY2025 · TW · contact PI
Functional profiling of OSP-specific and other antibodies during shigella infection$137,385
R01 · FY2025 · AI · contact PI
CK21-001 - Global TravEpiNet (GTEN): U.S. Travelers' Health Research, Surveillance, Communication and Outreach Network Supplement - Pregnant Travelers$50,000
U01 · FY2025 · CK
Shigella Conjugate Vaccine (SCV4) Development, Characterization, and Pre-clinical Evaluation$981,139
R01 · FY2024 · AI · contact PI
CK21-001 - Global TravEpiNet (GTEN): U.S. Travelers' Health Research, Surveillance, Communication and Outreach Network Supplement$899,992
U01 · FY2024 · CK
Functional profiling of OSP-specific and other antibodies during shigella infection$761,935
R01 · FY2024 · AI · contact PI
O-Specific Polysaccharide Responses and Cholera$739,887
R37 · FY2024 · AI · contact PI
International research training program in vaccine development and public health$253,751
D43 · FY2024 · TW · contact PI
CK21-001 - Global TravEpiNet (GTEN): U.S. Travelers' Health Research, Surveillance, Communication and Outreach Network Supplement - Pregnant Travelers$149,939
U01 · FY2024 · CK
Shigella Conjugate Vaccine (SCV4) Development, Characterization, and Pre-clinical Evaluation$1,010,389
R01 · FY2023 · AI · contact PI
Global TravEpiNet (GTEN): U.S. Travelers? Health Research, Surveillance, Communication and Outreach Network$800,000
U01 · FY2023 · CK
Functional profiling of OSP-specific and other antibodies during shigella infection$761,935
R01 · FY2023 · AI · contact PI
O-Specific Polysaccharide Responses and Cholera$739,887
R37 · FY2023 · AI · contact PI
International research training program in vaccine development and public health$285,001
D43 · FY2023 · TW · contact PI
Functional profiling of OSP-specific and other antibodies during shigella infection$761,935
R01 · FY2022 · AI · contact PI
O-Specific Polysaccharide Responses and Cholera$739,487
R37 · FY2022 · AI · contact PI
International research training program in vaccine development and public health$285,001
D43 · FY2022 · TW · contact PI
Global TravEpiNet (GTEN): U.S. Travelers' Health Research, Surveillance, Communication and Outreach Network Supplement$1,826,286
U01 · FY2021 · CK
Global TravEpiNet (GTEN): U.S. Travelers? Health Research, Surveillance, Communication and Outreach Network$1,498,119
U01 · FY2021 · CK
Functional profiling of OSP-specific and other antibodies during shigella infection$761,935
R01 · FY2021 · AI · contact PI
O-Specific Polysaccharide Responses and Cholera$739,487
R37 · FY2021 · AI · contact PI
International research training program in vaccine development and public health$287,001
D43 · FY2021 · TW · contact PI
Global TravEpiNet (GTEN): the Heading Home Healthy Program and Global Travelers' Health National Research Center Consortium, Guidance and Outreach Programs$1,406,400
U01 · FY2020 · CK · contact PI
Global TravEpiNet (GTEN): the Heading Home Healthy Program and Global Travelers' Health National Research Center Consortium, Guidance and Outreach Programs$1,406,400
U01 · FY2020 · CK · contact PI
Functional profiling of OSP-specific and other antibodies during shigella infection$780,195
R01 · FY2020 · AI · contact PI
O-Specific Polysaccharide Responses and Cholera$609,561
R37 · FY2020 · AI · contact PI
International research Training program in vaccine development and public health$249,930
D43 · FY2020 · TW · contact PI
O-Specific Polysaccharide Responses and Cholera$248,922
R56 · FY2020 · AI · contact PI
Global TravEpiNet (GTEN): the Heading Home Healthy Program and Global Travelers' Health National Research Center Consortium, Guidance and Outreach Programs$761,048
U01 · FY2019 · CK · contact PI
Global TravEpiNet (GTEN): the Heading Home Healthy Program and Global Travelers' Health National Research Center Consortium, Guidance and Outreach Programs$650,000
U01 · FY2019 · CK · contact PI
International research Training program in vaccine development and public health$249,930
D43 · FY2019 · TW · contact PI
Global TravEpiNet (GTEN): the Heading Home Healthy Program and Global Travelers' Health National Research Center Consortium, Guidance and Outreach Programs$3,335,150
U01 · FY2018 · CK · contact PI
O-Specific Polysaccharide Responses and Cholera$779,448
R01 · FY2018 · AI · contact PI
International research Training program in vaccine development and public health$249,930
D43 · FY2018 · TW · contact PI
Global TravEpiNet (GTEN): the Heading Home Healthy Program and Global Travelers' Health National Research Center Consortium, Guidance and Outreach Programs$1,880,567
U01 · FY2017 · CK · contact PI
O-Specific Polysaccharide Responses and Cholera$779,448
R01 · FY2017 · AI · contact PI
Global TravEpiNet (GTEN): the Heading Home Healthy Program and Global Travelers' Health National Research Center Consortium, Guidance and Outreach Programs$590,000
U01 · FY2017 · CK · contact PI
International research Training program in vaccine development and public health$249,930
D43 · FY2017 · TW · contact PI
Global TravEpiNet (GTEN): the Heading Home Healthy Program and Global Travelers' Health National Research Center Consortium, Guidance and Outreach Programs$794,938
U01 · FY2016 · CK · contact PI
O-Specific Polysaccharide Responses and Cholera$779,448
R01 · FY2016 · AI · contact PI
Improving diagnostic capabilities for typhoid fever$319,283
R33 · FY2016 · AI · contact PI
International research Training program in vaccine development and public health$251,930
D43 · FY2016 · TW · contact PI
Global TravEpiNet: Global Travelers' Health Surveillance, Applications, and Cons$972,405
U01 · FY2015 · CK · contact PI
O-Specific Polysaccharide Responses and Cholera$779,448
R01 · FY2015 · AI · contact PI
Improving diagnostic capabilities for typhoid fever$323,205
R33 · FY2015 · AI · contact PI
Training program in vaccine development and public health$242,433
D43 · FY2015 · TW · contact PI
Global TravEpiNet: Global Travelers' Health Surveillance, Applications, and Cons$755,000
U01 · FY2014 · CK · contact PI
Protecutive immunity to human cholera in Bangladesh$711,135
U01 · FY2014 · AI · contact PI
O-Specific Polysaccharide Responses and Cholera$552,123
R01 · FY2014 · AI · contact PI
Improving diagnostic capabilities for typhoid fever$344,952
R33 · FY2014 · AI · contact PI
Training program in vaccine development and public health$242,433
D43 · FY2014 · TW · contact PI
Global TravEpiNet: Global Travelers' Health Surveillance, Applications, and Cons$755,000
U01 · FY2013 · CK · contact PI
Protecutive immunity to human cholera in Bangladesh$668,466
U01 · FY2013 · AI · contact PI
O-Specific Polysaccharide Responses and Cholera$593,824
R56 · FY2013 · AI · contact PI
Training program in vaccine development and public health$236,611
D43 · FY2013 · TW · contact PI
Improving diagnostic capabilities for typhoid fever$196,385
R21 · FY2013 · AI · contact PI
High throughput NAPPA-proteoimmunomics and Vibrio cholerae vaccine development$1,089,549
U01 · FY2012 · AI · contact PI
Global TravEpiNet: Global Travelers' Health Surveillance, Applications, and Cons$755,000
U01 · FY2012 · CK · contact PI
Protecutive immunity to human cholera in Bangladesh$711,135
U01 · FY2012 · AI
Improving diagnostic capabilities for typhoid fever$279,312
R21 · FY2012 · AI · contact PI
Training program in vaccine development and public health$249,898
D43 · FY2012 · TW · contact PI
High throughput NAPPA-proteoimmunomics and Vibrio cholerae vaccine development$1,144,934
U01 · FY2011 · AI · contact PI
Global TravEpiNet: Global Travelers' Health Surveillance, Applications, and Cons$760,000
U01 · FY2011 · CK · contact PI
Protecutive immunity to human cholera in Bangladesh$710,453
U01 · FY2011 · AI
Training program in vaccine development and public health$249,931
D43 · FY2011 · TW · contact PI
High throughput NAPPA-proteoimmunomics and Vibrio cholerae vaccine development$1,079,893
U01 · FY2010 · AI · contact PI
Protecutive immunity to human cholera in Bangladesh$765,601
U01 · FY2010 · AI
Global TravEpiNet: Global Travelers' Health National Research Center Consortium$390,000
U19 · FY2010 · CI · contact PI
Training program in vaccine development$120,790
D43 · FY2010 · TW · contact PI
High throughput NAPPA-proteoimmunomics and Vibrio cholerae vaccine development$1,068,774
U01 · FY2009 · AI · contact PI
Global TravEpiNet: Global Travelers' Health National Research Center Consortium$550,000
U19 · FY2009 · CI · contact PI
Training program in vaccine development$133,950
D43 · FY2009 · TW · contact PI
Training program in vaccine development$106,750
D43 · FY2009 · TW · contact PI
High throughput NAPPA-proteoimmunomics and Vibrio cholerae vaccine development$1,233,253
U01 · FY2008 · AI · contact PI
Global TravEpiNet: Global Travelers' Health National Research Center Consortium$500,000
U19 · FY2008 · CI · contact PI
High throughput proteomic analysis of Salmonella enterica$214,594
R21 · FY2008 · AI · contact PI
Transcutaneous and oral-transcutaneous cholera immunization with TcpA and Peru15$164,771
R21 · FY2008 · AI · contact PI
Training program in vaccine development$141,717
D43 · FY2008 · TW · contact PI
Global TravEpiNet: Global Travelers' Health National Research Center Consortium$814,034
U19 · FY2007 · CI · contact PI
High throughput proteomic analysis of Salmonella enterica$251,250
R21 · FY2007 · AI · contact PI
Transcutaneous and oral-transcutaneous cholera immunization with TcpA and Peru15$200,641
R21 · FY2007 · AI · contact PI
Training program in vaccine development$133,950
D43 · FY2007 · TW · contact PI
Training program in vaccine development$79,548
D43 · FY2007 · TW · contact PI
Mucosal Immunity to Antigens Expressed by V.cholerae$377,297
R01 · FY2006 · AI · contact PI
Training program in vaccine development$127,500
D43 · FY2006 · TW · contact PI
Mucosal Immunity to Antigens Expressed by V.cholerae$386,377
R01 · FY2005 · AI
Mucosal Immunity to Antigens Expressed by V.cholerae$386,377
R01 · FY2004 · AI
Application of IVIAT to Bacillus anthracis$343,810
R21 · FY2004 · AI
Mucosal Immunity to Antigens Expressed by V.cholerae$386,377
R01 · FY2003 · AI
Application of IVIAT to Bacillus anthracis$273,000
R21 · FY2003 · AI
Mucosal Immunity to Antigens Expressed by V.cholerae$411,377
R01 · FY2002 · AI
V CHOLERAE AS A VECTOR FOR INDUCING MUCOSAL IMMUNITY$124,551
K08 · FY2000 · AI